These data suggest that AC-200 presents a unique dual benefit in CKD, potentially correcting not only mineral abnormalities but also reducing bone pathology associated with complications such as hip fracture in CKD patients. Results of AC-200 administration in this standardized CKD rodent model provide strong support for clinical advancement of AC-200 stated Dr. Dawn McGuire, Chief Medical Officer of Acologix. AC-200 presents a unique opportunity to address both pathologic and hyperphosphatemia bone loss, major complications of CKD, with a single agent. .. Acologix demonstrates improved bone architecture in rat style of chronic kidney disease Acologix, Inc.About the SPIRIT PRIME Clinical Trial SPIRIT Primary is a prospective, two-arm, open-label, multi-center registry designed to evaluate XIENCE Primary in 500 patients with coronary artery disease. The trial was carried out at more than 60 centers in the U.S. And Australia. Two registry arms were evaluated: the Primary Size arm and the Long Lesion arm. The Primary Size arm utilized XIENCE PRIME stents calculating 2.25 mm to 4.0 mm in diameter and from 8 mm to 28 mm in length. The Long Lesion arm used XIENCE Primary stents calculating 2.5 mm to 4.0 mm in diameter and either 33 mm or 38 mm in length.
Next Post: Luciano Candilio.